Why the study?
The mechanisms underlying the cardioprotective effects of SGLT2 inhibition remain largely unexplained, and prior studies evaluating myocardial energetics lacked the power to detect discrete effects.
Does SGLT2 inhibition reduce myocardial oxygen consumption?
Does SGLT2 inhibition reduce myocardial oxygen consumption?
SGLT2 inhibition reduces resting myocardial oxygen consumption, providing a potential mechanistic explanation for its cardioprotective effects.
Answers are grounded in this paper and cite their sources.
Reduces resting myocardial oxygen consumption; extends randomized evidence that improved energetics contribute to SGLT2i cardioprotection.
Aims/hypothesis: SGLT2 inhibition is associated with a reduced risk of cardiac disease that is still largely unexplained. According to one hypothesis, improved myocardial energetics may explain the cardioprotective effects of SGLT2i. However, recent mechanistic studies that have addressed this question have lacked the power to detect discrete but still clinically significant effects. Methods: We pooled data from two recent randomized clinical trials and performed a meta-analysis to determine the effect of SGLT2 inhibition on myocardial oxygen consumption and myocardial external efficiency measured by positron emission tomography. Results: SGLT2 inhibition reduced myocardial oxygen consumption (-1.06 [95%CI: 0.22-1.89] mL/100 g/min (n = 59, p = 0.01)), but did not affect myocardial external efficiency (2.22 [95%CI: 0.66-5.11] % (n = 59, p = 0.13)). interpretation: SGLT2 inhibition reduces myocardial oxygen consumption at rest, which may contribute to the drugs' cardioprotective effects.
No takes yet. Share an insight, caveat, or question.
Søndergaard et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: